For the first time in more than fifty years, the federal government is prepared to treat cannabis as something other than a substance with no accepted medical use. In April, the Department of Justice and the Drug Enforcement Administration formally proposed moving state-licensed medical cannabis and FDA-approved marijuana products from Schedule I to Schedule III under the Controlled Substances Act - a shift that, if finalized, would rewrite the legal foundation on which the entire medical cannabis industry has operated. Gretchen Gailey, President of Project Champion and a longstanding medical cannabis advocate, has been among those watching this development closely.
What Schedule I Actually Meant - and Why It Mattered So Much
Schedule I is the most restrictive classification in federal drug law. It carries a specific legal assertion: that a substance has no currently accepted medical use and a high potential for abuse. Heroin is Schedule I. So, until now, was cannabis - regardless of what dozens of state legislatures, medical boards, and patients had concluded over the past three decades.
That classification had real, structural consequences. It blocked most federally funded research. It prevented cannabis businesses from deducting ordinary business expenses under federal tax law - a provision known as 280E, which has imposed an enormous financial burden on state-licensed dispensaries. It made banking access difficult, kept cannabis off the formularies of most hospitals and health systems, and created a persistent legal contradiction: a patient could legally purchase medical cannabis in their home state and simultaneously be in violation of federal law.
Schedule III is a different category entirely. It covers substances with moderate to low potential for dependence and a recognized medical use - anabolic steroids and ketamine both sit there. The reclassification doesn't legalize cannabis federally in the way that recreational laws function at the state level, but it removes the most damaging legal fiction at the center of federal policy: the claim that cannabis has no medical value whatsoever.
A Long Time Coming, With Complications Still Ahead
The proposal didn't emerge from nowhere. It followed a 2022 directive from the Biden administration asking HHS to review cannabis scheduling - a review that concluded, after examining available clinical evidence, that cannabis met the threshold for Schedule III placement. That recommendation then moved to the DEA, which holds the formal rulemaking authority.
Here's the catch, though: this is still a proposed rule, not a final one. Federal rulemaking requires a public comment period, and the DEA must review those comments before issuing a final determination. That process can take months. Legal challenges are possible. The political environment is not static. What happened in April was a consequential step - but the finish line remains some distance away.
Advocates like Gailey, who has worked to build recognition for medical cannabis patients and their access needs, understand this well. The rescheduling proposal is a shift in federal posture, not a resolution of every tension that has accumulated between state cannabis law and federal prohibition. Interstate commerce, banking reform, and research access all involve regulatory and legislative threads that rescheduling alone doesn't fully untangle.
What Changes - and What Doesn't
If the rule is finalized, the most immediate and tangible change may be financial. Removal from Schedule I would likely eliminate the application of 280E to cannabis businesses, which has required dispensaries to pay federal taxes on gross revenue rather than net income - an arrangement that has driven some compliant businesses into insolvency. That change alone could alter the economics of the legal cannabis market in fundamental ways.
Research access would also shift. Schedule I status required researchers to navigate a bureaucratic process so cumbersome that it actively deterred study. Schedule III compounds face a less restrictive pathway, which could open the door to the kind of rigorous clinical trials that have been difficult to conduct - and that regulators, prescribers, and patients have long needed to make fully informed decisions.
What rescheduling won't do is resolve the federal-state divide at the consumer level. Cannabis would remain a controlled substance. It would not, under this change alone, become available through conventional pharmacies or covered by federal health insurance programs. The contradiction between state legality and federal control shrinks; it doesn't disappear.
Still. After half a century of Schedule I classification, the direction of travel has changed. That is not a small thing.
